Camurus AB (publ) (CAMRF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Camurus AB (publ) (CAMRF) with AI Score 63/100 (Hold). Camurus AB (publ) is a Swedish pharmaceutical company specializing in the development and commercialization of innovative medicines for severe and chronic conditions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Camurus AB (publ) (CAMRF) Healthcare & Pipeline Overview
Camurus AB (publ) develops and commercializes specialized medicines, particularly long-acting injectables, for chronic conditions like opioid dependence and acromegaly. With a focus on innovative drug delivery and a presence in Europe, Australia, the US, and Japan, Camurus operates in the competitive biotechnology sector, marked by high R&D investments and stringent regulatory requirements.
Investment Thesis
Camurus presents an investment opportunity predicated on its innovative FluidCrystal technology and expanding pipeline. The company's focus on long-acting injectables addresses the critical need for improved adherence in chronic disease management. Key value drivers include the continued uptake of Buvidal for opioid dependence, the potential approval and commercialization of CAM2029 for acromegaly, and the advancement of its pipeline assets. With a current P/E ratio of 38.10 and a profit margin of 32.5%, Camurus demonstrates strong profitability. Upcoming catalysts include clinical trial results for CAM2029 and CAM4072. However, potential risks include regulatory hurdles, competition from established pharmaceutical companies, and the inherent uncertainties of drug development.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $3.28 billion reflects investor confidence in Camurus's pipeline and commercial prospects.
- A P/E ratio of 38.10 suggests a premium valuation, indicating expectations of future growth.
- Gross margin of 92.8% demonstrates strong pricing power and efficient manufacturing processes.
- Profit margin of 32.5% highlights the company's ability to convert revenue into profit.
- Beta of 0.41 indicates lower volatility compared to the overall market, suggesting a relatively stable investment.
Competitors & Peers
Strengths
- Proprietary FluidCrystal injection depot technology.
- Established presence in key markets.
- Strong pipeline of drug candidates.
- High gross margin.
Weaknesses
- Reliance on a limited number of products.
- High R&D expenses.
- Dependence on regulatory approvals.
- Competition from larger pharmaceutical companies.
Catalysts
- Upcoming: Clinical trial results for CAM2029 in acromegaly and neuroendocrine tumors.
- Upcoming: Regulatory approval decisions for CAM2029 in key markets.
- Upcoming: Clinical trial results for CAM4072 in genetic obesity disorders.
- Ongoing: Expansion of Buvidal market share in Europe, Australia, the United States, and Japan.
- Ongoing: Advancement of pipeline assets through clinical development.
Risks
- Potential: Regulatory setbacks and delays in drug approvals.
- Potential: Competition from established pharmaceutical companies and generic drugs.
- Potential: Pricing pressures and reimbursement challenges.
- Ongoing: Dependence on the success of key products like Buvidal.
- Ongoing: High R&D expenses and the inherent risks of drug development.
Growth Opportunities
- Expansion of Buvidal Market Share: Buvidal, Camurus's buprenorphine injection for opioid dependence, has significant growth potential. The opioid addiction crisis continues to drive demand for effective treatment options. Camurus can expand its market share by increasing awareness among healthcare providers, securing favorable reimbursement policies, and expanding its geographic reach. The global opioid dependence treatment market is projected to reach billions of dollars, providing a substantial opportunity for Camurus.
- Commercialization of CAM2029 for Acromegaly: CAM2029, Camurus's investigational drug for acromegaly and neuroendocrine tumors, is in Phase III clinical trials. Successful completion of these trials and subsequent regulatory approval would represent a major growth catalyst. The market for acromegaly treatments is estimated to be substantial, and CAM2029's long-acting formulation could offer a significant advantage over existing therapies. The timeline for potential commercialization is dependent on clinical trial outcomes and regulatory review.
- Advancement of CAM2032 for Prostate Cancer: CAM2032, currently in Phase II clinical trials for prostate cancer, represents another significant growth opportunity. Prostate cancer is a prevalent disease, and new treatment options are continuously sought. Positive clinical trial results could lead to regulatory approval and commercialization, expanding Camurus's oncology portfolio. The prostate cancer therapeutics market is a multi-billion dollar market, offering significant revenue potential.
- Development of CAM4072 for Genetic Obesity Disorders: Camurus is developing CAM4072 for the treatment of genetic obesity disorders, currently in Phase III clinical trials. Obesity is a growing global health concern, and genetic forms of obesity often lack effective treatments. Successful development and commercialization of CAM4072 could address a significant unmet medical need and generate substantial revenue. The obesity therapeutics market is experiencing rapid growth, driven by the increasing prevalence of the disease.
- Pipeline Expansion with Novel Drug Delivery Systems: Camurus's proprietary FluidCrystal technology provides a platform for developing a range of long-acting injectable formulations. The company can leverage this technology to expand its pipeline with new drug candidates targeting various therapeutic areas. This includes CAM2043, CAM4071, CAM2047 and CAM2048. By continuously innovating and expanding its pipeline, Camurus can sustain long-term growth and maintain a competitive edge in the pharmaceutical industry.
Opportunities
- Expansion into new geographic markets.
- Development of new drug candidates using FluidCrystal technology.
- Strategic partnerships and collaborations.
- Increasing demand for long-acting injectable formulations.
Threats
- Regulatory setbacks.
- Competition from generic drugs.
- Pricing pressures.
- Product liability claims.
Competitive Advantages
- Proprietary FluidCrystal technology creates a barrier to entry for competitors.
- Strong intellectual property protection for its drug formulations.
- Established commercial infrastructure in key markets.
- Clinical data supporting the efficacy and safety of its products.
- Strategic partnerships with pharmaceutical companies for co-development and commercialization.
About CAMRF
Founded in 1991 and headquartered in Lund, Sweden, Camurus AB (publ) is a pharmaceutical company focused on developing and commercializing innovative medicines for the treatment of severe and chronic conditions. The company's core expertise lies in its proprietary FluidCrystal injection depot technology, which enables the development of long-acting injectable formulations. Camurus's flagship product is Buvidal, a buprenorphine injection used for the treatment of opioid dependence. Other products include episil oral liquid, a medical device for oral pain relief, and Brixadi for opioid use disorder. The company's pipeline includes CAM2038 for chronic pain, CAM2029 for acromegaly and neuroendocrine tumors, and CAM2043 for pulmonary arterial hypertension and Raynaud's phenomenon. Camurus operates in Europe, Australia, the United States, and Japan, marketing its products through a combination of its own sales force and partnerships. Camurus aims to improve patient outcomes and adherence through its innovative drug delivery systems.
What They Do
- Develops long-acting injectable medicines using FluidCrystal technology.
- Commercializes Buvidal for the treatment of opioid dependence.
- Offers episil oral liquid for the treatment of oral pain.
- Develops CAM2029 for the treatment of acromegaly and neuroendocrine tumors.
- Develops CAM2032 for the treatment of prostate cancer.
- Develops CAM4072 for the treatment of genetic obesity disorders.
- Conducts clinical trials to advance its pipeline of drug candidates.
Business Model
- Develops proprietary pharmaceutical products using its FluidCrystal technology.
- Out-licenses or co-develops products with pharmaceutical partners.
- Generates revenue through product sales in Europe, Australia, the United States, and Japan.
- Focuses on long-acting injectables for chronic conditions to improve patient adherence.
Industry Context
Camurus operates within the biotechnology sector, characterized by intense R&D, stringent regulatory oversight, and high growth potential. The market for long-acting injectables is expanding, driven by the need for improved patient adherence and convenience. Camurus competes with established pharmaceutical companies and other biotechnology firms developing novel drug delivery systems. The industry is subject to evolving regulatory landscapes and pricing pressures. Camurus's focus on chronic conditions and its proprietary FluidCrystal technology position it to capitalize on the growing demand for innovative drug therapies.
Key Customers
- Patients suffering from opioid dependence.
- Patients with acromegaly and neuroendocrine tumors.
- Patients experiencing chronic pain.
- Healthcare providers prescribing Camurus's medications.
- Hospitals and clinics administering Camurus's injectable products.
Financials
Chart & Info
Camurus AB (publ) (CAMRF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Friday
· Jan 17, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CAMRF.
Price Targets
Wall Street price target analysis for CAMRF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CAMRF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Fredrik Tiberg
CEO
Fredrik Tiberg serves as the CEO of Camurus AB (publ). His background includes extensive experience in the pharmaceutical industry, with a focus on drug delivery and product development. He has held various leadership positions within Camurus, contributing to the company's growth and strategic direction. Tiberg's expertise spans research, development, and commercialization of pharmaceutical products. He is responsible for overseeing the company's operations and driving its innovation efforts.
Track Record: Under Fredrik Tiberg's leadership, Camurus has achieved significant milestones, including the successful development and commercialization of Buvidal. He has overseen the expansion of the company's pipeline and the advancement of key drug candidates through clinical trials. Tiberg has also played a crucial role in establishing strategic partnerships and collaborations to support Camurus's growth. He manages 238 employees.
CAMRF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Camurus AB (publ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the potential for less transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in CAMRF.
- Thin trading volume can lead to price volatility and difficulty in executing trades.
- Lower regulatory oversight compared to major exchanges.
- Potential for fraud or manipulation due to less stringent listing requirements.
- Information asymmetry can disadvantage investors.
- Verify the company's registration and legal standing.
- Thoroughly review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a qualified financial advisor.
- Research the company's history and any past controversies.
- Camurus AB (publ) is a publicly traded company, suggesting a degree of transparency.
- The company has a history of developing and commercializing pharmaceutical products.
- Camurus has established partnerships with reputable pharmaceutical companies.
- The company's products have received regulatory approvals in key markets.
- Camurus has a dedicated management team and a clear business strategy.
Camurus AB (publ) Stock: Key Questions Answered
What does Camurus AB (publ) do?
Camurus AB (publ) is a pharmaceutical company that develops and commercializes innovative medicines for severe and chronic conditions. The company's core technology is its FluidCrystal injection depot, which enables the creation of long-acting injectable formulations. Camurus's key products include Buvidal for opioid dependence, episil oral liquid for oral pain, and Brixadi for opioid use disorder. The company operates in Europe, Australia, the United States, and Japan, focusing on improving patient outcomes and adherence through its novel drug delivery systems.
What do analysts say about CAMRF stock?
Analyst opinions on CAMRF stock are pending AI analysis. Key valuation metrics to consider include the company's P/E ratio of 38.10, gross margin of 92.8%, and profit margin of 32.5%. Growth considerations include the potential for Buvidal market expansion, the successful development and commercialization of pipeline assets, and the company's ability to leverage its FluidCrystal technology. Investors should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
What are the main risks for CAMRF?
The main risks for CAMRF include regulatory setbacks, competition from established pharmaceutical companies and generic drugs, pricing pressures, dependence on the success of key products like Buvidal, and the high R&D expenses and inherent risks of drug development. Additionally, as an OTC-listed stock, CAMRF faces risks associated with limited liquidity, less stringent regulatory oversight, and potential for information asymmetry. Investors should carefully consider these risks before investing in CAMRF.
What are the key factors to evaluate for CAMRF?
Camurus AB (publ) (CAMRF) currently holds an AI score of 63/100, indicating moderate score. Key strength: Proprietary FluidCrystal injection depot technology.. Primary risk to monitor: Potential: Regulatory setbacks and delays in drug approvals.. This is not financial advice.
How frequently does CAMRF data refresh on this page?
CAMRF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CAMRF's recent stock price performance?
Recent price movement in Camurus AB (publ) (CAMRF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary FluidCrystal injection depot technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CAMRF overvalued or undervalued right now?
Determining whether Camurus AB (publ) (CAMRF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CAMRF?
Before investing in Camurus AB (publ) (CAMRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending may provide further insights.
- OTC market investments carry additional risks.